Analysis of Beneficial Effects of Flavonoids in Patients with Atherosclerosis Risk on Blood Pressure or Cholesterol during Random Controlled Trials: A Systematic Review and Meta-Analysis

IF 2.3 Q3 PHARMACOLOGY & PHARMACY
Rosa Edith Grijalva-Guiza, Thais Lucía Grijalva-Montano, Mariana Cuautle, E. Quiroga‐González, L. R. Hernández, Alicia Ortega Aguilar, A. M. Jiménez-Garduño
{"title":"Analysis of Beneficial Effects of Flavonoids in Patients with Atherosclerosis Risk on Blood Pressure or Cholesterol during Random Controlled Trials: A Systematic Review and Meta-Analysis","authors":"Rosa Edith Grijalva-Guiza, Thais Lucía Grijalva-Montano, Mariana Cuautle, E. Quiroga‐González, L. R. Hernández, Alicia Ortega Aguilar, A. M. Jiménez-Garduño","doi":"10.3390/scipharm91040055","DOIUrl":null,"url":null,"abstract":"Flavonoids are plant-secondary metabolites with cardiovascular protective properties. Few studies have examined specific flavonoid classes or pure flavonoids concerning some common cardiovascular risks. To obtain information in a systematic review to analyze in a meta-analysis, data were recovered regarding flavonoid intake in random controlled trials and atherosclerosis disease, related to risk factors such as blood pressure, total cholesterol (TC), and low-density lipoprotein cholesterol (LDLc). Our aim was to conduct a meta-analysis using the Scopus and PubMed databases without restrictions on the year of publication, extracting articles over the period 1–15 April 2023, searching for randomized controlled trials (RCTs) that investigated different types of flavonoids, measuring blood pressure and low-density cholesterol plasmatic concentration. This paper’s Prospero registration is CRD 42023414153. There were 19 RCTs: twelve RCTs were considered for blood pressure data analysis and fifteen RCTs for total cholesterol and LDL cholesterol data analysis. The meta-analysis showed no significant differences between placebo treatments and treatments with different flavonoids on blood pressure. However, there was a significant difference found in quantitative analysis for TC and LDLc. In conclusion, flavonoid consumption can be associated with a lower risk of LDLc and TC, and more RCTs are needed to specify the effect of more types of pure flavonoids in atherosclerotic patients.","PeriodicalId":21601,"journal":{"name":"Scientia Pharmaceutica","volume":"8 1","pages":""},"PeriodicalIF":2.3000,"publicationDate":"2023-11-22","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"Scientia Pharmaceutica","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.3390/scipharm91040055","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"PHARMACOLOGY & PHARMACY","Score":null,"Total":0}
引用次数: 0

Abstract

Flavonoids are plant-secondary metabolites with cardiovascular protective properties. Few studies have examined specific flavonoid classes or pure flavonoids concerning some common cardiovascular risks. To obtain information in a systematic review to analyze in a meta-analysis, data were recovered regarding flavonoid intake in random controlled trials and atherosclerosis disease, related to risk factors such as blood pressure, total cholesterol (TC), and low-density lipoprotein cholesterol (LDLc). Our aim was to conduct a meta-analysis using the Scopus and PubMed databases without restrictions on the year of publication, extracting articles over the period 1–15 April 2023, searching for randomized controlled trials (RCTs) that investigated different types of flavonoids, measuring blood pressure and low-density cholesterol plasmatic concentration. This paper’s Prospero registration is CRD 42023414153. There were 19 RCTs: twelve RCTs were considered for blood pressure data analysis and fifteen RCTs for total cholesterol and LDL cholesterol data analysis. The meta-analysis showed no significant differences between placebo treatments and treatments with different flavonoids on blood pressure. However, there was a significant difference found in quantitative analysis for TC and LDLc. In conclusion, flavonoid consumption can be associated with a lower risk of LDLc and TC, and more RCTs are needed to specify the effect of more types of pure flavonoids in atherosclerotic patients.
在随机对照试验中分析黄酮类化合物对有动脉粥样硬化风险的患者的血压或胆固醇的有益影响:系统回顾与元分析
类黄酮是植物的次级代谢产物,具有保护心血管的特性。很少有研究针对一些常见的心血管风险对特定类黄酮或纯类黄酮进行研究。为了在系统综述中获取信息并进行荟萃分析,我们在随机对照试验中收集了有关类黄酮摄入量和动脉粥样硬化疾病的数据,这些数据与血压、总胆固醇(TC)和低密度脂蛋白胆固醇(LDLc)等风险因素有关。我们的目的是利用Scopus和PubMed数据库进行荟萃分析,不限制发表年份,提取2023年4月1日至15日期间的文章,搜索研究不同类型类黄酮、测量血压和低密度胆固醇质浓度的随机对照试验(RCT)。本文的 Prospero 注册号为 CRD 42023414153。共有 19 项 RCT:其中 12 项 RCT 用于血压数据分析,15 项 RCT 用于总胆固醇和低密度胆固醇数据分析。荟萃分析表明,安慰剂疗法和不同类黄酮疗法对血压的影响没有显著差异。不过,在对总胆固醇和低密度脂蛋白胆固醇进行定量分析时,发现两者之间存在明显差异。总之,食用类黄酮与降低低密度脂蛋白胆固醇和高密度脂蛋白胆固醇的风险有关,需要进行更多的研究与试验,以明确更多种类的纯类黄酮对动脉粥样硬化患者的影响。
本文章由计算机程序翻译,如有差异,请以英文原文为准。
求助全文
约1分钟内获得全文 求助全文
来源期刊
Scientia Pharmaceutica
Scientia Pharmaceutica Pharmacology, Toxicology and Pharmaceutics-Pharmaceutical Science
CiteScore
4.60
自引率
4.00%
发文量
67
审稿时长
10 weeks
×
引用
GB/T 7714-2015
复制
MLA
复制
APA
复制
导出至
BibTeX EndNote RefMan NoteFirst NoteExpress
×
提示
您的信息不完整,为了账户安全,请先补充。
现在去补充
×
提示
您因"违规操作"
具体请查看互助需知
我知道了
×
提示
确定
请完成安全验证×
copy
已复制链接
快去分享给好友吧!
我知道了
右上角分享
点击右上角分享
0
联系我们:info@booksci.cn Book学术提供免费学术资源搜索服务,方便国内外学者检索中英文文献。致力于提供最便捷和优质的服务体验。 Copyright © 2023 布克学术 All rights reserved.
京ICP备2023020795号-1
ghs 京公网安备 11010802042870号
Book学术文献互助
Book学术文献互助群
群 号:481959085
Book学术官方微信